PROTECT YOURSELF with Orgo-Life® QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by Adpathway- Coherus BioSciences press release (CHRS): Q4 Non-GAAP EPS of -$0.34 misses by $0.03.
- Revenue of $12.7M (+64.9% Y/Y) misses by $1.39M.
More on Coherus BioSciences
- Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114
- Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
- Coherus BioSciences Q4 2025 Earnings Preview
- Coherus Oncology prices stock offering to raise $50.1M
English (US) · 
French (CA) · 
French (FR) ·